Celly Nutrition Secures Investment Bank Partner to Fuel Growth and IPO Plans
Quantum BioPharma (QNTM), a biopharmaceutical company focused on innovative biotech solutions, announced that its licensee, Celly Nutrition Corporation, has engaged a leading New York investment bank to raise up to $10 million and explore an initial public offering (IPO) on a major U.S. exchange.
Celly Nutrition, the company behind unbuzzd™—a scientifically proven beverage that accelerates alcohol metabolism and reduces hangover symptoms—signed a Letter of Engagement (LOE) on February 4, 2025. The investment bank will provide financial advisory services, including guidance on uplisting to a major U.S. exchange, a reverse merger, or another public market transaction. Additionally, the bank will act as the exclusive managing underwriter and sole book running manager for a proposed $10 million public offering.
John Duffy, CEO of Celly Nutrition and a former executive at Coca-Cola, emphasized the significance of this move. “This is an important milestone for Celly Nutrition and unbuzzd. Having successfully launched in the U.S. market in 2024, our focus in 2025 is to raise additional capital to accelerate marketing, retail expansion, and direct-to-consumer sales,” he stated.
Gerry David, Co-Chair of Celly’s Board and former CEO of Celsius Holdings, echoed this optimism. “We have found the perfect investment banking partner to guide us through this capital raise and IPO. There is strong interest in unbuzzd, and we want to give investors the opportunity to be part of its growth.”
As unbuzzd gains traction, Celly Nutrition’s efforts to secure funding and go public signal ambitious expansion plans for the breakthrough beverage.
You might like this article: Inspira Technologies Enhances AI-Powered HYLA Blood Sensor with Advanced Oxygenation Indicator
